Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,275 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Age-dependent and gender-dependent antibody responses against SARS-CoV-2 in health workers and octogenarians after vaccination with the BNT162b2 mRNA vaccine.
Terpos E, Trougakos IP, Apostolakou F, Charitaki I, Sklirou AD, Mavrianou N, Papanagnou ED, Liacos CI, Gumeni S, Rentziou G, Korompoki E, Papassotiriou I, Dimopoulos MA. Terpos E, et al. Among authors: dimopoulos ma. Am J Hematol. 2021 Jul 1;96(7):E257-E259. doi: 10.1002/ajh.26185. Epub 2021 Apr 24. Am J Hematol. 2021. PMID: 33837984 Free PMC article. No abstract available.
Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose.
Terpos E, Trougakos IP, Gavriatopoulou M, Papassotiriou I, Sklirou AD, Ntanasis-Stathopoulos I, Papanagnou ED, Fotiou D, Kastritis E, Dimopoulos MA. Terpos E, et al. Among authors: dimopoulos ma. Blood. 2021 Jul 1;137(26):3674-3676. doi: 10.1182/blood.2021011904. Blood. 2021. PMID: 33861315 Free PMC article. No abstract available.
Comparison of neutralizing antibody responses against SARS-CoV-2 in healthy volunteers who received the BNT162b2 mRNA or the AZD1222 vaccine: Should the second AZD1222 vaccine dose be given earlier?
Terpos E, Trougakos IP, Karalis V, Ntanasis-Stathopoulos I, Sklirou AD, Bagratuni T, Papanagnou ED, Patseas D, Gumeni S, Malandrakis P, Korompoki E, Dimopoulos MA. Terpos E, et al. Among authors: dimopoulos ma. Am J Hematol. 2021 Sep 1;96(9):E321-E324. doi: 10.1002/ajh.26248. Epub 2021 Jun 2. Am J Hematol. 2021. PMID: 34028867 Free PMC article. No abstract available.
The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment.
Terpos E, Gavriatopoulou M, Ntanasis-Stathopoulos I, Briasoulis A, Gumeni S, Malandrakis P, Fotiou D, Papanagnou ED, Migkou M, Theodorakakou F, Roussou M, Eleutherakis-Papaiakovou E, Kanellias N, Trougakos IP, Kastritis E, Dimopoulos MA. Terpos E, et al. Among authors: dimopoulos ma. Blood Cancer J. 2021 Aug 2;11(8):138. doi: 10.1038/s41408-021-00530-3. Blood Cancer J. 2021. PMID: 34341335 Free PMC article.
Kinetics of Anti-SARS-CoV-2 Antibody Responses 3 Months Post Complete Vaccination with BNT162b2; A Prospective Study in 283 Health Workers.
Terpos E, Trougakos IP, Karalis V, Ntanasis-Stathopoulos I, Gumeni S, Apostolakou F, Sklirou AD, Gavriatopoulou M, Skourti S, Kastritis E, Korompoki E, Papassotiriou I, Dimopoulos MA. Terpos E, et al. Among authors: dimopoulos ma. Cells. 2021 Jul 30;10(8):1942. doi: 10.3390/cells10081942. Cells. 2021. PMID: 34440710 Free PMC article.
Kinetics of anti-SARS-CoV-2 neutralizing antibodies development after BNT162b2 vaccination in patients with amyloidosis and the impact of therapy.
Kastritis E, Terpos E, Evangelakou Z, Theodorakakou F, Fotiou D, Manola MS, Gianniou DD, Bagratuni T, Kanellias N, Migkou M, Gavriatopoulou M, Trougakos IP, Dimopoulos MA. Kastritis E, et al. Among authors: dimopoulos ma. Am J Hematol. 2022 Jan 1;97(1):E27-E31. doi: 10.1002/ajh.26406. Epub 2021 Nov 23. Am J Hematol. 2022. PMID: 34778995 Free PMC article. Clinical Trial. No abstract available.
Third dose of the BNT162b2 vaccine results in very high levels of neutralizing antibodies against SARS-CoV-2: Results of a prospective study in 150 health professionals in Greece.
Terpos E, Karalis V, Sklirou AD, Apostolakou F, Ntanasis-Stathopoulos I, Bagratuni T, Iconomidou VA, Malandrakis P, Korompoki E, Papassotiriou I, Trougakos IP, Dimopoulos MA. Terpos E, et al. Among authors: dimopoulos ma. Am J Hematol. 2022 Apr;97(4):E147-E150. doi: 10.1002/ajh.26468. Epub 2022 Jan 25. Am J Hematol. 2022. PMID: 35025124 Free PMC article. No abstract available.
Immune response and adverse events after vaccination against SARS-CoV-2 in adult patients with transfusion-dependent thalassaemia.
Delaporta P, Terpos E, Solomou EE, Gumeni S, Nitsa E, Apostolakou F, Kyriakopoulou D, Ntanasis-Stathopoulos I, Papassotiriou I, Trougakos IP, Dimopoulos MA, Kattamis A. Delaporta P, et al. Among authors: dimopoulos ma. Br J Haematol. 2022 Jun;197(5):576-579. doi: 10.1111/bjh.18146. Epub 2022 Mar 14. Br J Haematol. 2022. PMID: 35286720 Free PMC article.
Low neutralizing antibody responses in WM, CLL and NHL patients after the first dose of the BNT162b2 and AZD1222 vaccine.
Gavriatopoulou M, Terpos E, Kastritis E, Briasoulis A, Gumeni S, Ntanasis-Stathopoulos I, Sklirou AD, Malandrakis P, Eleutherakis-Papaiakovou E, Migkou M, Trougakos IP, Dimopoulos MA. Gavriatopoulou M, et al. Among authors: dimopoulos ma. Clin Exp Med. 2022 May;22(2):319-323. doi: 10.1007/s10238-021-00746-4. Epub 2021 Jul 20. Clin Exp Med. 2022. PMID: 34283338 Free PMC article.
1,275 results